scholarly journals Use of an Open-Source Software to Examine Low Skeletal Muscle Mass in Penile Cancer Patients: A Cross-Sectional Study

Author(s):  
C. Ibilibor ◽  
H. Wang ◽  
D. Kaushik ◽  
R. Rodriguez

Purpose: Low skeletal muscle mass determined radiographically has emerged as an important prognostic marker in penile cancer patients but may be unrecognized in obese patients with a high comorbid disease burden. Moreover, publicly available software for image segmentation are limited. Thus, we describe the prevalence of radiographically low skeletal muscle mass in an obese penile cancer cohort, using an open-source software and examine its association with comorbid disease burden. Methods: This is a cross-sectional study, utilizing retrospective data from patients diagnosed with penile squamous cell carcinoma between October 2009 and December 2019. Available digital files of perioperative computerized tomography were analyzed, using CoreSlicer, an open-source image segmentation software. The correlation between radiographically low skeletal muscle mass, defined as a skeletal muscle index (SMI) less than 55 cm2/m2 and a Charlson Comorbidity Index (CCI) greater than 4 was examined, using logistic and linear regression. Results: Forty two of 59 patients had available digital files. Median SMI and body mass index (BMI) were 54.6cm2/m2 and 30.2kg/m2 respectively for the entire cohort. Of included patients, 54% had radiographically low skeletal muscle mass and a median BMI of 28.9 kg/m2. Radiographically low skeletal muscle mass was associated with a CCI greater than 4 on univariable and multivariable logistic regression with odds ratios of 4.85 (p = 0.041) and 7.32 (p = 0.033), respectively. When CCI was treated as a continuous variable on linear regression, the association between radiographically low skeletal muscle mass and CCI was positive, but not statistically significant with an estimated effect of 1.29 (p = 0.1) and 1.27 (p = 0.152) on univariable and multivariable analysis, respectively. Conclusion: Our data demonstrate that low skeletal muscle mass can be readily assessed with CoreSlicer and is associated with a CCI greater than 4 in obese penile cancer patients.

2017 ◽  
Vol 135 (5) ◽  
pp. 434-443 ◽  
Author(s):  
Ricardo Aurélio Carvalho Sampaio ◽  
Priscila Yukari Sewo Sampaio ◽  
Luz Albany Arcila Castaño ◽  
João Francisco Barbieri ◽  
Hélio José Coelho Júnior ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Tatiana de Paula ◽  
Mauren de Freitas ◽  
Vanessa Lopes ◽  
Maria Elisa Miller ◽  
Karen Araujo ◽  
...  

Abstract Objectives The aim of the study was to establish the prevalence of sarcopenia and associated factors in elderly with type 2 diabetes (DM) in southern Brazil. Methods A cross-sectional study was performed in 240 patients with type 2 DM. The diagnosis of sarcopenia was performed according to EWGSOP criteria. Muscle mass was calculated by skeletal muscle mass index (appendicular skeletal muscle mass/height² - Inbody® bioimpendance). Muscle strength was assessed by manual grip strength (Jamar® dynamometer) and physical performance was assessed by the sit and lift test. Patients with type 2 DM with age ≥60 years and with the ability to ambulate were selected. Patients with recent cardiovascular events, serum creatinine >2.0 mg/dl, use of corticosteroids and BMI >40 kg/m² were excluded. The sample size was 240 patients based on meta-analysis who found 17% sarcopenia in elderly patients without DM. Results We included 240 patients aged 68.4 ± 5.5 years, 53.2% were women and the duration of DM was 15 (8–22) years, the BMI was 29.4 ± 4.4 kg/m². The prevalence of sarcopenia was 21% and men had more sarcopenia (75%). Patients with sarcopenia walk less [3541 (2227–4574) vs. 4521 (3037–5678) steps, P = 0.013], drink more alcohol [21 (56.8%) vs. 71 (31.8%); P < 0.034] and have lower total cholesterol levels [146 ± 41 Vs. 168 ± 43; P = 0.007] than the group without sarcopenia. In multivariate logistic regression models, walking < 3760 steps [OR = 2868; CI 95% 1.331–6.181] and male [OR = 5285; CI 95% 2261–12,350], were associated with sarcopenia. Conclusions The prevalence of sarcopenia was 21%, higher than in patients without diabetes (17%). In this group of patients, lower physical activity, and male sex were associated with sarcopenia. Funding Sources FIPE n. 160467; CAPES.


Maturitas ◽  
2007 ◽  
Vol 56 (4) ◽  
pp. 404-410 ◽  
Author(s):  
Marco Di Monaco ◽  
Fulvia Vallero ◽  
Roberto Di Monaco ◽  
Rosa Tappero ◽  
Alberto Cavanna

2021 ◽  
Author(s):  
Aliyu Tijani Jibril ◽  
Atieh Mirzababaei ◽  
Farideh Shiraseb ◽  
Niloufar Rasaei ◽  
Khadijeh Mirzaei

Abstract Objectives Obesity is a major risk factor for metabolic syndrome, with its prevalence has increased over the past decade. Major changes in body composition with aging have a significant effect on many clinical outcomes. Sarcopenic obesity consists of both the presence of abnormal adipose tissue with a deficit of muscle mass. Results Of the 241 subjects in this study (average age 35.32 years), 176 (73.03%) were classified as MUO phenotype. Based on this study, the prevalence of sarcopenic obesity was 7.88%. We found that high fat-free mass was more strongly and significantly associated with MUO phenotype. Furthermore, we found that individuals with high fat-free mass and high skeletal muscle mass had a significantly low prevalence of MUO phenotype. A significant positive correlation between metabolic phenotypes and sarcopenic obesity was also observed after all potential covariates were adjusted for. These results of this study suggest that increased adiposity and decreased skeletal muscle mass are associated with unfavorable metabolic traits among overweight and obese Iranian women. SO was also found to be associated with a greater risk of developing MUO phenotype.


Author(s):  
Bruno Raynard ◽  
Frederic Pigneur ◽  
Mario Di Palma ◽  
Elise Deluche ◽  
François Goldwasser

Abstract Background Cachexia, characterized by involuntary muscle mass loss, negatively impacts survival outcomes, treatment tolerability, and functionality in cancer patients. However, there is a limited appreciation of the true prevalence of low muscle mass due to inconsistent diagnostic methods and limited oncologist awareness. Methods Twenty-nine French healthcare establishments participated in this cross-sectional study, recruiting patients with those metastatic cancers most frequently encountered in routine practice (colon, breast, kidney, lung, prostate). The primary outcome was low skeletal muscle mass prevalence, as diagnosed by estimating the skeletal mass index (SMI) in the middle of the third-lumbar vertebrae (L3) level via computed tomography (CT). Other objectives included an evaluation of nutritional management, physical activity, and toxicities related to ongoing treatment. Results Seven hundred sixty-six patients (49.9% males) were enrolled with a mean age of 65.0 years. Low muscle mass prevalence was 69.1%. Only one-third of patients with low skeletal muscle mass were receiving nutritional counselling and only 28.4% were under nutritional management (oral supplements, enteral or parenteral nutrition). Physicians highly underdiagnosed those patients identified with low skeletal muscle mass, as defined by the primary objective, by 74.3% and 44.9% in obese and non-obese patients, respectively. Multivariate analyses revealed a lower risk of low skeletal muscle mass for females (OR: 0.22, P < 0.01) and those without brain metastasis (OR: 0.34, P < 0.01). Low skeletal muscle mass patients were more likely to have delayed treatment administration due to toxicity (11.9% versus 6.8%, P = 0.04). Conclusions There is a critical need to raise awareness of low skeletal muscle mass diagnosis among oncologists, and for improvements in nutritional management and physical therapies of cancer patients to curb potential cachexia. This calls for cross-disciplinary collaborations among oncologists, nutritionists, physiotherapists, and radiologists.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1425.2-1425
Author(s):  
E. Jalila ◽  
H. Azzouzi ◽  
I. Linda

Background:Patients with rheumatoid arthritis (RA) were at risk for altered body composition with higher prevalence of sarcopenia compared to the general population. Low lean muscle mass may constitute an additional risk factor for altered bone density in RA patients.Objectives:We aimed to study the prevalence of sarcopenia and to assess its predictive factors in Moroccan patients with RA.Methods:We conducted a cross-sectional study over two months in our department of rheumatology. All RA patients fulfilled ACR/EULAR 2010 criteria. We performed a whole-body dual-energy X-ray absorptiometry (DXA) to measure lean mass, fat mass and bone mass in the whole body and body parts. The appendicular skeletal muscle mass was assessed using the sum of skeletal muscle mass in the arms and legs. The relative skeletal muscle mass index (RSMI) was calculated from the appendicular skeletal mass divided by the square of the patient’s height (kg/m2). According to Baumgartner et al, sarcopenia was defined as a relative SMI <5.5 kg/m2on women and <7.26 kg/m2on men. Body mass index (BMI) was measured and patients were classified according to World Health Organization. Disease activity and functional disability were measured using the 28-joint Disease Activity Score (DAS28) with CRP and the Health Assessment Questionnaire (HAQ). Comorbidities and medication use including corticosteroids were also recorded. Data was entered and processed using the IBM SPSS Statistics 20. A univariate analysis as well as multivariate regressions were carried out to assess the association between sarcopenia and lumbar spine and femoral neck (FN) bone mineral density (BMD) and RA characteristics.Results:We included 70 (87.5%) women and 10 (12.5%) men with a mean age of 53.59 ±10.96 years old. They had a mean disease duration of 12.35± 8.68, a mean DAS 28 CRP of 2.64±1.34, a mean HAQ of 0.94±0.63 and a mean RSMI of 5.75±1.17. Women had a mean RSMI of 6.33±1.04 while men had a mean RSMI of 5.66±1.17. The prevalence of sarcopenia in our population was 47.4% (37), of whom 81.1% (30) women.In univariate regression analysis, sarcopenia was associated with normal BMI (OR: 8.59, 95% CI [3.054-24.182], p= 0.000), DAS 28 CRP (OR: 1.78, 95% CI [1.203-2.657], p= 0.004), HAQ (OR: 2.15, 95% CI [1.165-5.433], p= 0.019), lumbar spine BMD (OR: 0.001, 95% CI [0.00001-0.043], p= 0.0004) and FN BMD (OR: 0.000006, 95% CI [0.000-0.002], p= 0,00008 at right FN and OR: 0.00009, 95% CI [0.000001-0.010], p=0.000 at left FN, respectively).In multiple regression analysis, sarcopenia was associated with normal BMI (OR: 11.56, 95% CI [2.754–48.598]), p=0.001 and FN BMD (OR: 0.00, 95% CI [0.000–0.084], p = 0.006).Conclusion:In the present study, sarcopenia was common among RA patients and associated with normal BMI and femoral neck BMD, emphasizing the importance of this modifiable risk factor. Further studies are needed to identify effective means to improve lean muscle mass in patients with RA.References:[1]Mochizuki T et al. Sarcopenia-associated factors in Japanese patients with rheumatoid arthritis: A cross-sectional study. Geriatr. Gerontol. Int. 2019;19 (9), 907-912[2]Okano T et al. Loss of lean body mass affects low bone mineral density in patients with rheumatoid arthritis -results from the TOMORROW study-, Modern Rheumatology. 2017;27(6):1-19.[4]Peggy M. Cawthon. Assessment of Lean Mass and Physical Performance in Sarcopenia. Journal of Clinical Densitometry. 2015;18(4):467-71.Disclosure of Interests:None declared


2021 ◽  
Author(s):  
Pedro Pugliesi Abdalla ◽  
Ana Cláudia Rossini Venturini ◽  
André Pereira dos Santos ◽  
Marcio Tasinafo ◽  
José Augusto Gonçalves Marini ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kwan Ho Lee ◽  
Seoung Wan Chae ◽  
Ji Sup Yun ◽  
Yong Lai Park ◽  
Chan Heun Park

AbstractMammographic density (MD) of the breast and body mass index (BMI) are inversely associated with each other, but have inconsistent associations with respect to the risk of breast cancer. Skeletal muscle mass index (SMI) has been considered to reflect a relatively accurate fat and muscle percentage in the body. So, we evaluated the relation between SMI and MD. A cross-sectional study was performed in 143,456 women who underwent comprehensive examinations from 2012 to 2016. BMI was adjusted to analyze whether SMI is an independent factor predicting dense breast. After adjustment for confounding factors including BMI, the odds ratios for MD for the dense breasts was between the highest and lowest quartiles of SMI at 2.65 for premenopausal women and at 2.39 for postmenopausal women. SMI was a significant predictor for MD, which could be due to the similar growth mechanism of the skeletal muscle and breast parenchymal tissue. Further studies are needed to understand the causal link between muscularity, MD and breast cancer risk.


Sign in / Sign up

Export Citation Format

Share Document